TheraRadar
Data updated: Jul 17, 2026

PARAGARD T 380A (copper) · COOPERSURGICAL

Women's Health Approved 1984-11-15

Paragard is a copper-containing intrauterine system used to prevent pregnancy in females of reproductive potential. It provides long-term contraceptive protection for up to 10 years. This system is placed within the uterus to help patients manage their reproductive health over an extended period.

Source: FDA Label • Copper-containing Intrauterine Device

How PARAGARD T 380A Works

Paragard works by continuously releasing copper into the uterine cavity. This copper interferes with sperm transport and the fertilization of an egg; it may also prevent implantation.

6
Indications
--
Phase 3 Trials
41
Years on Market

Details

Status
Prescription
First Approved
1984-11-15
Patent Cliff
2027

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INTRAUTERINE
Dosage Forms
SYSTEM

Companies

Active Ingredient: COPPER

PARAGARD T 380A Approval History

1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
54 FDA actions from 1984 to 2024 · 5 indication expansions
Jun 2024 SUPPL
Efficacy
Sep 2019 SUPPL
Label · Labeling
Feb 2014 SUPPL
Mfg · Manufacturing (CMC)

What PARAGARD T 380A Treats

1 indications

PARAGARD T 380A is approved for 1 conditions since its original approval in 1984. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Prevention of pregnancy

Same approved indications as MIUDELLA (same active ingredient).

Source: FDA Label
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT01777919 GLIODIS PK-18081973 Ph 2 not yet recruiting Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform
NCT04265274 BREAST-SK-001 Ph 2 withdrawn Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
NCT02963051 Pro00071007 Ph 1 terminated A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PARAGARD T 380A FDA Label Details

Indications & Usage

FDA Label (PDF)

Paragard is indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. Paragard is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 10 years.

PARAGARD T 380A Patents & Exclusivity

Exclusivity: Jun 2027

Exclusivity

D-193 Until Jun 2027
Source: FDA Orange Book

Track PARAGARD T 380A with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.